Clinical Trial Update: An Open-label, Multicenter, Single-arm Clinical Study on the Use of Doxorubicin Liposome in Combination With CapOX and Bevacizumab Regimen for First-line Treatment of Advanced Colorectal Adenocarcinoma With SMAD4R361H/C Mutation. [Phase 1, Phase 2]

View source ↗

Summary

An open-label, multicenter, single-arm Phase 1/2 study evaluating a doxorubicin liposome-containing regimen with CapOX and bevacizumab as first-line therapy for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Doxorubicin liposome (doxorubicin liposomal)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Advanced Colorectal Adenocarcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING